Fosamax class action

On March 2010, the FDA began a safety review of Fosamax to determine whether or not there is an increase in the risk of bone fractures.  The agency is investigating the possible link between Fosamax and fractures that occur below the hip joint on patients who have been on bisphosphonates for several years.  The investigation is still on going but the FDA suggests that for patients who are currently on bisphosphonates should continue therapy but should make sure they talk to their healthcare providers if they develop any symptoms.